Elekta AB Reports Strong Q4 Performance with Best Gross Margin in Five Years

Elekta AB ( ($SE:EKTA.B) ) has provided an announcement.

Elekta AB reported a 6% increase in net sales for the fourth quarter of 2024/25 at constant exchange rates, driven by strong performance in Europe and APAC, and a 3% increase in reported sales. The company achieved its best fourth-quarter gross margin in five years at 40.3%, supported by price increases, product launches, and a solid performance of its Elekta Evo linear accelerator and Elekta ONE software suite. Despite a non-cash impairment of SEK 1,064 M due to discontinued R&D projects, Elekta maintained a strong book-to-bill ratio and improved cash flow. The company expects continued sales growth and margin improvements, aiming to reach pre-pandemic levels, while its products have received positive feedback from healthcare providers.

The most recent analyst rating on ($SE:EKTA.B) stock is a Sell with a SEK67.00 price target. To see the full list of analyst forecasts on Elekta AB stock, see the SE:EKTA.B Stock Forecast page.

More about Elekta AB

Elekta AB operates in the medical technology industry, specializing in the development and production of clinical solutions for the treatment of cancer and brain disorders. The company’s primary products include linear accelerators and software solutions, with a market focus on Europe and the Asia-Pacific region.

Average Trading Volume: 1,251,274

Current Market Cap: SEK18.78B

For detailed information about EKTA.B stock, go to TipRanks’ Stock Analysis page.